--- title: "Hims & Hers Health Posts Mixed Q1 Amid Weight-Loss Product 'Noise': Analysts" type: "News" locale: "en" url: "https://longbridge.com/en/news/286130715.md" description: "Hims & Hers Health reported disappointing Q1 results, leading to a 14.07% drop in shares. Revenue was $608 million, missing estimates, while EBITDA fell to $44.3 million. Analysts had mixed reactions: JPMorgan maintained an Overweight rating but lowered the price target to $33; Needham kept a Buy rating and raised the target to $35; BTIG reaffirmed a Neutral rating. The company raised its 2026 revenue outlook despite lowering EBITDA guidance by $25 million, citing concerns over margin pressure from the shift to branded GLP-1s." datetime: "2026-05-12T16:01:17.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286130715.md) - [en](https://longbridge.com/en/news/286130715.md) - [zh-HK](https://longbridge.com/zh-HK/news/286130715.md) --- # Hims & Hers Health Posts Mixed Q1 Amid Weight-Loss Product 'Noise': Analysts Shares of **Hims & Hers Health Inc (NYSE:HIMS)** tanked in early trading on Tuesday, after the company Monday reported disappointing first-quarter results. Here are the key analyst insights: - JPMorgan analyst Cory Carpenter reiterated an Overweight rating, while cutting the price target from $35 to $33. - Needham analyst Ryan MacDonald maintained a Buy rating, while lifting the price target from $30 to $35. - BTIG analyst David Larsen reaffirmed a Neutral rating on the stock. **Check out other analyst stock ratings**. **JPMorgan:** Hims & Hers Health reported mixed results, amid "noise" created by the shift from compounded to Novo-branded GLP-1s (glucagon-like peptide-1 receptor agonists), Carpenter said in a note. The company reported revenue of $608 million, representing 4% year-on-year growth, which was "no worse than feared," while strong Wegovy uptake led management to raise their 2026 revenue outlook, he added. Hims & Hers Health guided to second-quarter revenue of $680-$700 million, representing 27% year-on-year growth, while raising the 2026 revenue outlook from $2.7-$2.9 billion to $2.8-$3.0 billion, the analyst stated. While the 2026 EBITDA outlook was lowered by $25 million, stroking concerns over the shift to branded impacting the company's margins, management said the reduction was due to "transitory factors," he further wrote. **Needham:** Hims & Hers Health reported revenue of $608.1 million and adjusted EBITDA of $44.3 million, missing consensus estimates of $617 million and $47 million, respectively, MacDonald said. Subscribers grew 9.2% year-on-year and 2.9% sequentially to 2.584 million, he added. The renewed partnership with **Novo Nordisk** (NYSE:NVO) is triggering strong demand, and Hims & Hers Health is on track to add 100,000 new weight-loss subscribers per month, the analyst stated. The Novo partnership helps to bring in numerous net new subs for HIMS to create “cross-sell multiple categories of care like labs, testosterone and menopause care," he further wrote. **BTIG:** Hims & Hers Health's adjusted EBITDA contracted by 51% year-on-year to $44.3 million and fell significantly short of expectations. The company also raised its 2026 revenue outlook. However, management reduced adjusted EBITDA guidance from $300-$375 million to $275-$350 million. "Our view is that the branded GLP-1s are far lower-margin than the compounded GLP-1s, and the transition to branded products is putting significant pressure on EBITDA," the analyst wrote. **HIMS Price Action:** Shares of Hims & Hers Health had declined by 14.07% to $25.04 at the time of publication on Tuesday. **Read Also: Claude Grew 10x Faster Than ChatGPT In April — Is OpenAI Losing AI Power Users?** _Image: Shutterstock_ ### Related Stocks - [HIMS.US](https://longbridge.com/en/quote/HIMS.US.md) - [HIMY.US](https://longbridge.com/en/quote/HIMY.US.md) - [HIMZ.US](https://longbridge.com/en/quote/HIMZ.US.md) - [JPM.US](https://longbridge.com/en/quote/JPM.US.md) - [NVO.US](https://longbridge.com/en/quote/NVO.US.md) - [OpenAI.NA](https://longbridge.com/en/quote/OpenAI.NA.md) - [SSTK.US](https://longbridge.com/en/quote/SSTK.US.md) - [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md) - [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md) - [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md) - [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md) - [8634.JP](https://longbridge.com/en/quote/8634.JP.md) - [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md) - [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md) ## Related News & Research - [Why Hims & Hers Health stock just crashed](https://longbridge.com/en/news/286133577.md) - [Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?](https://longbridge.com/en/news/286135059.md) - [$1000 Invested In Hims & Hers Health 5 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/286630207.md) - [Hims prices $350M 0.00% convertible notes due 2032, upsized from $300M](https://longbridge.com/en/news/286911997.md) - [BUZZ-Hims & Hers Health shares stabilize after boosted $350 mln convertible deal](https://longbridge.com/en/news/286896810.md)